Postmarketing surveillance of elobixibat for patients with chronic constipation and concomitant schizophrenia or depression in Japan - Takeaways - MDSpire

Postmarketing surveillance of elobixibat for patients with chronic constipation and concomitant schizophrenia or depression in Japan

  • By

  • Yoshiteru Takekita

  • Minami Umeyama

  • Mie Iwaida

  • Masaaki Higashikawa

  • Yusuke Shimada

  • Atsushi Nakajima

  • April 20, 2026

  • 0 min

Share

  • 1

    Elobixibat is a novel laxative that improves chronic constipation by inhibiting the ileal bile acid transporter.

  • 2

    A postmarketing study in Japan assessed elobixibat's safety and effectiveness in patients with chronic constipation and psychiatric comorbidities.

  • 3

    The study included 105 patients with schizophrenia and 129 with depression in the 4-week treatment group.

  • 4

    Elobixibat significantly increased defecation frequency and improved stool consistency in patients with schizophrenia and depression.

  • 5

    Adverse drug reactions were low, with diarrhea being the most common, and no serious adverse events were reported.

Original Source(s)

Postmarketing surveillance of elobixibat for patients with chronic constipation and concomitant schizophrenia or depression in Japan

  • by Yoshiteru Takekita, Minami Umeyama, Mie Iwaida, Masaaki Higashikawa, Yusuke Shimada, Atsushi Nakajima

  • April 20, 2026

Related Content

Assessment of Anxiety and Depression Rates and Their Risk Factors in Gastroenterology Outpatients: A Multicenter Cross-Sectional Analysis

Abdominal wall hernia and mental health: patients lived experiences and implications for patient care

Vascular and autonomic correlates of screening-positive depressive symptom burden in chronic atrophic gastritis: a multicenter observational study protocol